Transplant Genomics offers a test that assesses differentially expressed genes in blood to rule out subclinical kidney transplant rejection.
The acquisition will bring to Invitae single-molecule, cell-free DNA analysis technology and enable lower cost NIPS testing.
Bratislava-based HighChem offers software that is used by pharmaceutical and metabolomics laboratories for analyzing complex data and identifying small molecules.
Cytobank provides a cloud- and machine learning-based software platform for multi-parametric single-cell data analysis, sharing, and archiving.
The company has formalized an existing relationship by acquiring Pharmatech, hoping to directly integrate the firm's "right on time" trial matching service with its own molecular testing.
The company's new KidneyCare test will include AlloSure for rejection, AlloMap for quiescence, and Cibiltech's AI algorithm for graft health information.
The company reported $26 million in total revenues for the quarter and said that testing services revenues more than doubled year over year.
Cincinnati, Ohio-based Meridian will acquire Quebec City-based GenePOC for $120 million, and hopes to quickly convert customers to a PCR-based instrument.
The firms will integrate Caris' molecular profiling services with Pharmatech's clinical trials recruitment and network services to further precision medicine.
Elucigene has been developing in vitro diagnostics for oncology and reproductive health, including tests for cystic fibrosis screening and prenatal fetal aneuploidy screening.
Russian CRISPR researcher moves along with plans to ultimately alter the genes of embryos of deaf couples, though awaits regulatory approval, Nature News reports.
University of California, San Francisco, researchers have uncovered a gene mutations that appears to make a father-son duo more efficient sleepers.
NPR reports a large health insurer has begun to cover some pharmacogenetic tests for psychiatric drugs.
In PLOS this week: genome-wide association study of non-syndromic orofacial cleft subtypes, epigenetic and transcriptomic analysis of pancreatic ductal adenocarcinoma, and more.